Equities Analysts Issue Forecasts for DBVT FY2028 Earnings

Key Points

• HC Wainwright raised its FY2028 EPS forecast for DBV Technologies to $1.25 from $1.15, although analysts still expect a current-year loss of $2.05 per share.
• DBV reported a quarterly loss of $0.70 per share, missing the $0.26 consensus estimate, while revenue of $1.60 million exceeded expectations.
• Analyst sentiment remains generally positive, with five Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $46.50 average price target; the stock recently opened at $10.29.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities researchers at HC Wainwright upped their FY2028 earnings estimates for shares of DBV Technologies in a research report issued to clients and investors on Thursday, October 29th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.25 for the year, up from their prior forecast of $1.15. The consensus estimate for DBV Technologies' current full-year earnings is ($2.05) per share.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.44). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.56 million. DBV Technologies had a negative return on equity of 115.81% and a negative net margin of 5,392.17%.

DBVT has been the topic of several other research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Citigroup reissued a "market outperform" rating on shares of DBV Technologies in a research note on Thursday. Weiss Ratings restated a "sell (e+)" rating on shares of DBV Technologies in a report on Thursday, October 15th. Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Finally, Citizens Jmp lowered their target price on DBV Technologies from $55.00 to $47.00 and set a "market outperform" rating on the stock in a research report on Thursday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, DBV Technologies has an average rating of "Moderate Buy" and a consensus target price of $46.50.

DBV Technologies Price Performance

NASDAQ DBVT opened at $10.29 on Friday. The stock has a market capitalization of $647.01 million, a P/E ratio of -3.42 and a beta of -1.04. The business has a 50 day simple moving average of $11.62 and a 200 day simple moving average of $16.97. DBV Technologies has a one year low of $8.63 and a one year high of $26.18.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in DBV Technologies by 170.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company's stock worth $249,000 after acquiring an additional 13,600 shares during the period. Vontobel Holding Ltd. bought a new position in shares of DBV Technologies during the 3rd quarter valued at approximately $144,000. Perceptive Advisors LLC bought a new position in shares of DBV Technologies during the 1st quarter valued at approximately $20,146,000. Vivo Capital LLC increased its stake in shares of DBV Technologies by 8.4% during the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after purchasing an additional 205,943 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth approximately $21,159,000. Institutional investors own 71.74% of the company's stock.

Key DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV submitted its Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children ages 4–7 and requested Priority Review. The company is also accelerating commercial preparations for a potential U.S. launch, which could be a major catalyst if the application is accepted and approved. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
• Positive Sentiment: The company reported $165.7 million in cash and equivalents as of September 30, 2026, which management said provides funding into the third quarter of 2027. This reduces near-term financing pressure while the regulatory process advances. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
• Positive Sentiment: Citizens JMP maintained a “market outperform” rating, indicating continued confidence in the long-term opportunity despite reducing its price target to $47 from $55. DBV Technologies Price Target Lowered at Citizens
• Neutral Sentiment: Third-quarter revenue was $1.60 million, above the $0.58 million analyst estimate, but the result remains small relative to the company’s development and commercialization costs. DBV Technologies Third-Quarter Earnings Results
• Negative Sentiment: DBV reported a quarterly loss of $0.70 per share, substantially worse than the $0.29 loss analysts expected. The company continues to report deeply negative margins and return on equity. DBV Technologies Reports Wider Third-Quarter Loss
• Negative Sentiment: The price-target reduction reflects concerns about manufacturing risk during the company’s transition toward commercial readiness, making regulatory and production execution key near-term risks. DBV Technologies Third-Quarter 2026 Earnings Call Transcript

DBV Technologies Company Profile

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.